Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
The study titled Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice and published in Hormone and Metabolic Research indicates that 58% of patients reported side effects mostly concerning the gastrointestinal tract. In addition, more than 20% of the participants quit the drug because of intolerable side effects. This study certainly put Novo Nordisk on risk of bowel injuries associated with the use of Ozempic
Proposed mechanisms include autonomic nervous system modulation and potential direct cardiac effects via GLP-1 receptors
Whether your clients are just getting started or struggling with side effects like low appetite, nausea, or confusion about what to eat, this GLP-1-friendly 7-day meal plan gives them clarity and structure
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (SELECT): [9] A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO): [10] Trial Finds Bimagrumab Aids Weight Loss in Patients With T2D, Obesity
Your provider may recommend a temporary dose pause or adjustment to establish better tolerability before advancing
